Overview

A Study of IXAZOMIB in Adult Patients With Lymphoma

Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, multicenter, phase 1, dose-escalation study of IXAZOMIB in adult patients with lymphoma. This study will be the first to administer IXAZOMIB to patients with lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Treatments:
Glycine
Ixazomib
Proteasome Inhibitors